Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : American Association for the Advancement of Science, [2015]-
    • Subject Terms:
      Alzheimer Disease*/pathology ; Amyloidosis*/complications ; Cognitive Dysfunction*/etiology; Amyloid beta-Peptides ; Antibodies ; Australia ; Biomarkers ; Cross-Sectional Studies ; Disease Progression ; Humans ; tau Proteins
    • Abstract:
      The pathological relevance of naturally occurring antibodies to β-amyloid (NAbs-Aβ) in Alzheimer's disease (AD) remains unclear. We aimed to investigate their levels and associations with Aβ burden and cognitive decline in AD in a cross-sectional cohort from China and a longitudinal cohort from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. NAbs-Aβ levels in plasma and cerebrospinal fluid (CSF) were tested according to their epitopes. Levels of NAbs targeting the amino terminus of Aβ increased, and those targeting the mid-domain of Aβ decreased in both CSF and plasma in AD patients. Higher plasma levels of NAbs targeting the amino terminus of Aβ and lower plasma levels of NAbs targeting the mid-domain of Aβ were associated with higher brain amyloidosis at baseline and faster cognitive decline during follow-up. Our findings suggest a dynamic response of the adaptive immune system in the progression of AD and are relevant to current passive immunotherapeutic strategies.
      (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
    • References:
      J Neuroimmunol. 2007 May;186(1-2):181-92. (PMID: 17477976)
      J Alzheimers Dis. 2019;70(3):811-824. (PMID: 31282413)
      J Neurochem. 2012 Mar;120(5):732-40. (PMID: 22188568)
      Ann Neurol. 2019 Aug;86(2):215-224. (PMID: 31168802)
      Age Ageing. 2003 Mar;32(2):205-10. (PMID: 12615566)
      Nat Neurosci. 2015 Dec;18(12):1725-7. (PMID: 26551546)
      J Biol Chem. 2005 Apr 29;280(17):17458-63. (PMID: 15728175)
      Lancet Neurol. 2013 Mar;12(3):218-9. (PMID: 23375966)
      Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16742-7. (PMID: 12481027)
      Nature. 1999 Jul 8;400(6740):173-7. (PMID: 10408445)
      Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12145-50. (PMID: 19581601)
      Drug Discov Today. 2013 Dec;18(23-24):1212-20. (PMID: 23954180)
      Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. (PMID: 25443857)
      Adv Exp Med Biol. 2012;750:91-9. (PMID: 22903668)
      EMBO Mol Med. 2016 Jun 01;8(6):595-608. (PMID: 27025652)
      Nature. 2016 Aug 31;537(7618):50-6. (PMID: 27582220)
      J Neuroimmunol. 2014 Sep 15;274(1-2):168-73. (PMID: 25022335)
      J Mol Neurosci. 2020 Aug;70(8):1208-1215. (PMID: 32212051)
      Nat Rev Immunol. 2006 May;6(5):404-16. (PMID: 16639431)
      Neurology. 2013 Jan 8;80(2):169-75. (PMID: 23255825)
      Nat Rev Neurol. 2019 Feb;15(2):73-88. (PMID: 30610216)
      N Engl J Med. 2014 Jan 23;370(4):311-21. (PMID: 24450890)
      Nat Rev Neurol. 2014 Apr;10(4):188-9. (PMID: 24638135)
      Alzheimers Dement. 2017 Sep;13(9):1004-1012. (PMID: 28253478)
      Am J Pathol. 2001 Jan;158(1):63-73. (PMID: 11141480)
      Alzheimers Res Ther. 2017 Dec 8;9(1):95. (PMID: 29221491)
      Biol Psychiatry. 2005 Apr 1;57(7):813-6. (PMID: 15820240)
      Neurology. 2011 Apr 26;76(17):1485-91. (PMID: 21490316)
      Brain. 2019 May 1;142(5):1441-1457. (PMID: 31032851)
      Lancet Neurol. 2010 Apr;9(4):363-72. (PMID: 20189881)
      Int Psychogeriatr. 2009 Aug;21(4):672-87. (PMID: 19470201)
      Neuromolecular Med. 2003;3(1):29-39. (PMID: 12665674)
      PLoS One. 2015 Mar 17;10(3):e0119632. (PMID: 25781335)
      Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. (PMID: 29067341)
      Alzheimers Dement. 2011 Jul;7(4):367-85. (PMID: 21784348)
    • Accession Number:
      0 (Amyloid beta-Peptides)
      0 (Antibodies)
      0 (Biomarkers)
      0 (tau Proteins)
    • Publication Date:
      Date Created: 20210201 Date Completed: 20220415 Latest Revision: 20220415
    • Publication Date:
      20250114
    • Accession Number:
      PMC7775771
    • Accession Number:
      10.1126/sciadv.abb0457
    • Accession Number:
      33523832